Chemung Canal Trust Co. lifted its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 208.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 206,403 shares of the biopharmaceutical company’s stock after purchasing an additional 139,550 shares during the period. Pfizer accounts for 1.2% of Chemung Canal Trust Co.’s portfolio, making the stock its 27th largest holding. Chemung Canal Trust Co.’s holdings in Pfizer were worth $5,973,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of the company. Olistico Wealth LLC acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $25,000. MFA Wealth Advisors LLC acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $29,000. Quarry LP acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $31,000. Creekmur Asset Management LLC bought a new stake in shares of Pfizer during the 4th quarter worth approximately $32,000. Finally, Trivant Custom Portfolio Group LLC lifted its holdings in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Trading Up 0.5 %
Shares of PFE traded up $0.15 during trading hours on Friday, hitting $28.49. 8,512,716 shares of the stock were exchanged, compared to its average volume of 37,278,957. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $33.92. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The business has a 50-day moving average of $29.21 and a 200-day moving average of $28.31. The firm has a market capitalization of $161.44 billion, a P/E ratio of -474.67, a price-to-earnings-growth ratio of 1.25 and a beta of 0.67.
Analysts Set New Price Targets
A number of analysts have recently weighed in on PFE shares. Barclays upped their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Thursday. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, UBS Group upped their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Nine investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $34.54.
View Our Latest Analysis on PFE
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
- Five stocks we like better than Pfizer
- What is the Hang Seng index?
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- P/E Ratio Calculation: How to Assess Stocks
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Profitably Trade Stocks at 52-Week Highs
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.